Shenzhen New Industries Biomedical Engineering Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Shenzhen New Industry Biomedical Engineering Co., Ltd. was established in 1995 and is a national high-tech enterprise specializing in the research and development, production, sales, and services of in vitro diagnostic products. Its registered capital is 786.66 million RMB. Since its establishment, the company has been focusing on research in the field of chemiluminescence immunoassay. After more than ten years of dedicated efforts, it successfully completed the registration of China's first fully automated chemiluminescence instrument in September 2008 and successfully launched it on the market. Through continuous technological innovation, the company successfully launched its intelligent "modular biochemical immune analysis system" in 2016, further enriching its product line. In July 2017, New Industry Biology passed the FDA 510 (k) review in the United States, becoming the first chemiluminescence manufacturer in China to obtain FDA approval. In 2018, New Industry Biology successfully released the ultra high speed fully automatic chemiluminescence immunoassay system MAGLUMIX8, ushering in a new era of chemiluminescence ultra high speed. In July 2019, the hepatitis C chemiluminescence product independently developed by New Industry Biology successfully passed the EU CEListA certification, becoming the first chemiluminescence manufacturer in China to obtain EU CE certification for hepatitis C reagents. In December 2020, New Industry Biology obtained China's first IVDRCE certification in the field of chemiluminescence, marking a new milestone on the global path of pioneers in the field of in vitro diagnostics. New Industry Biology is the first company in China to have a patent for "immune magnetic microspheres" as a key separation material for chemiluminescence systems, and the first company in China to have a patent for "artificially synthesized small molecule organic compound ABEI" and use it as a luminescent marker instead of traditional enzymes, At the same time, it is also the first company in China to apply the aforementioned patented technology, obtain domestic registration certificates, and achieve mass production of fully automatic direct chemiluminescence immunoassay instruments and supporting reagents. The company's research and development achievements have filled the gap in the field of in vitro diagnosis in China, breaking the long-standing monopoly and technological blockade of foreign manufacturers in this field, and have become a leader in the field of chemiluminescence immunoassay quantitative analysis in China. The company's main business: ① Fully automated chemiluminescence immunoassay instruments: MAGLUMIX8, MAGLUMIX3, MAGLUMIX6, MAGLUMI800, MAGLUMI1000, MAGLUMI2000, MAGLUMI2000Plus, MAGLUMI4000, MAGLUMI4000Plus; Supporting chemiluminescence reagents: 156 detection items, including thyroid function, sex hormones, tumor markers, myocardial markers, preoperative eight items, eugenics and fertility, glucose metabolism, bone metabolism, liver fibrosis, inflammation monitoring, and autoimmune antibodies; ② Intelligent assembly line for the entire laboratory: new industry - Thermofly SATLARS-TCA, new industry - Hitachi SMP/SMT, CX8 high-speed biochemical immune assembly line and supporting reagents, SIB ultra high-speed biochemical immune assembly line and supporting reagents, HX8 ultra high-speed biochemical immune assembly line and supporting reagents; ③ Fully automatic biochemical analysis instruments: BiossaysC8, BiossayBC1200, BiossayBC2200; Supporting biochemical reagents: blood fat, liver function, kidney function, myocardial markers, diabetes and other test items; ④ Fully automatic nucleic acid extraction and purification instruments: MolexionMP-96, MolexionMP-32, and supporting extraction reagents. As of the end of June 2022, the company has more than 2600 employees, including over 400 doctoral, master's, and overseas returnees. The company has professional teams such as reagent R&D and production centers, instrument R&D and manufacturing centers, and marketing centers to support the rapid development of the company. The reagent R&D and production center has an annual production capacity of 4 million boxes of reagents; The instrument research and development and manufacturing center has an annual production capacity of 3000 fully automated chemiluminescence analyzers and 1500 modular biochemical immune analysis systems; The company's domestic marketing and service network has covered all regions of the country, and the company is actively expanding overseas markets. Currently, it has established cooperative relationships with hospitals in 150 countries and regions such as Italy, Spain, France, and Colombia. The company continues to fulfill our mission: customer-centric, market-oriented, and continuously creating value for human life and health through continuous product and technological innovation. |
| Headquarter | Shenzhen |
| Establish Date | 12/15/1995 |
| Listed Code | 300832.SZ |
| Listed Date | 5/12/2020 |
| Chairman | Rao Wei. |
| CEO | Rao Wei. |
| Website | www.snibe.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
